MeiraGTx Holdings Gross Profit 2017-2021 | MGTX

MeiraGTx Holdings gross profit from 2017 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
MeiraGTx Holdings Annual Gross Profit
(Millions of US $)
2020 $16
2019 $13
2018 $
2017 $
2016 $
MeiraGTx Holdings Quarterly Gross Profit
(Millions of US $)
2021-09-30 $7
2021-06-30 $5
2021-03-31 $5
2020-12-31 $4
2020-09-30 $5
2020-06-30 $2
2020-03-31 $4
2019-12-31 $7
2019-09-30 $4
2019-06-30 $2
2019-03-31 $1
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.798B $0.016B
MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09